sorafenib,durvalumab,tremelimumab
astrazeneca,pfizer
['durva', 'hcc', 'himalaya', 'bcsm', 'tremelimumab']
tremelimumab plus durvalumab (stride) showed a manageable immune-related adverse event profile in the phase 3 himalaya trial. #oncology #nursing #iraes #immunotherapy #hcc #hpbcsm #asco23 
Capturing the voice of nursing professionals in the oncology news landscape.